Debt-to-equity of Cytek Biosciences, Inc. from 31 Mar 2022 to 31 Dec 2025
- Taxonomy & unit
- ratio: x
- Description
- Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's debt by its shareholder equity.
- Summary
-
Cytek Biosciences, Inc. quarterly Debt-to-equity in x history and change rate from 31 Mar 2022 to 31 Dec 2025.
- Cytek Biosciences, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 0.31x, a 19% increase year-over-year.
Debt-to-equity, Quarterly (x)
Debt-to-equity, YoY Quarterly Change (%)
Cytek Biosciences, Inc. Quarterly Debt-to-equity (x)
| Period | Value | YoY Chg | Change % | Date |
|---|---|---|---|---|
| Q4 2025 | 0.31x | +0.05x | +19% | 31 Dec 2025 |
| Q3 2025 | 0.29x | +0.03x | +11% | 30 Sep 2025 |
| Q2 2025 | 0.28x | +0.03x | +11% | 30 Jun 2025 |
| Q1 2025 | 0.26x | +0.01x | +5.2% | 31 Mar 2025 |
| Q4 2024 | 0.26x | +0.01x | +5% | 31 Dec 2024 |
| Q3 2024 | 0.26x | +0.02x | +8.6% | 30 Sep 2024 |
| Q2 2024 | 0.25x | +0.03x | +12% | 30 Jun 2024 |
| Q1 2024 | 0.25x | +0.04x | +16% | 31 Mar 2024 |
| Q4 2023 | 0.25x | +0.04x | +21% | 31 Dec 2023 |
| Q3 2023 | 0.24x | +0.05x | +29% | 30 Sep 2023 |
| Q2 2023 | 0.22x | +0.06x | +35% | 30 Jun 2023 |
| Q1 2023 | 0.21x | +0.02x | +10% | 31 Mar 2023 |
| Q4 2022 | 0.2x | 31 Dec 2022 | ||
| Q3 2022 | 0.18x | 30 Sep 2022 | ||
| Q2 2022 | 0.17x | 30 Jun 2022 | ||
| Q1 2022 | 0.19x | 31 Mar 2022 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.